Dinan

This research aims to assess the impact of an interprofessional education program IPEP on healthcare students collaboration skills during their clinical placements in multidisciplinary primary care centers MPCC. The study compares students who receive IPEP during their MPCC placements with those who undergo placements without this program. The IPEP is delivered by trained healthcare professionals within the MPCCs to enhance interprofessional collaboration IPC. The study involves two groups an intervention group where 12 MPCCs participate, each having 3 professionals trained to implement the IPEP for students and a control group of 12 MPCCs where students complete their clinical placements as usual without the IPEP. The trained professionals receive instruction through a train the trainer program led by an educational team before delivering the IPEP. Participants will be observed during their clinical placements, with assessments comparing student scores on the Interprofessional Collaborative Competency Attainment Survey ICCAS before and after placement. Qualitative studies will explore students perceptions and feelings about interprofessional collaboration in both groups. The study duration includes 18 months for quantitative assessments and 24 months for qualitative components.

Researchers are conducting an ambispective, observational, multicenter, and multicohort study focusing on patients with non-small cell lung cancer NSCLC who are starting treatments with approved drugs developed by AstraZeneca or its alliance partners. The study includes three groups based on the stage of NSCLC resectable, unresectable, and metastatic. This modular study is designed to evaluate patients receiving these drugs once they have European marketing authorization and are available in the participating countries. Patients will be observed whether they have already received, are currently receiving, or will receive approved AstraZeneca drugs as monotherapy or in combination at any disease stage. The study tracks patients independently of treatment decisions made by their doctors. Each cohort represents a different stage of NSCLC, allowing specific assessment for each group. Participants will be followed to collect real-world data on outcomes such as disease-free survival, event-free survival, treatment failure times, response rates, progression-free survival, and overall survival over periods ranging from 3 to 5 years. Researchers will analyze treatment responses, recurrence-free survival, and treatment discontinuation times among other measures. The study involves no intervention from researchers on treatment plans and focuses on monitoring outcomes in routine clinical practice.